The price of Nurix Therapeutics Inc. (NASDAQ:NRIX) shares last traded on Wall Street rose 5.66% to $9.52.
Based on available information, 13 analysts follow Nurix Therapeutics Inc. (NASDAQ:NRIX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $53.00 and a low of $11.00, we find $30.00. Given the previous closing price of $9.01, this indicates a potential upside of 232.96 percent. NRIX stock price is now -10.94% away from the 50-day moving average and -25.70% away from the 200-day moving average. The market capitalization of the company currently stands at $454.58M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Among analysts, 1 rate the stock a hold while 10 rate it a buy. Brokers who have rated the stock have averaged $29.62 as their price target over the next twelve months.
With the price target of $20, Barclays recently initiated with Overweight rating for Nurix Therapeutics Inc. (NASDAQ: NRIX). On February 28, 2023, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $25, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.
In other news, Hansen Gwenn, Chief Scientific Officer sold 1,412 shares of the company’s stock on Jan 30. The stock was sold for $16,633 at an average price of $11.78. Upon completion of the transaction, the Chief Scientific Officer now directly owns 23,009 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 30, Chief Financial Officer van Houte Hans sold 924 shares of the business’s stock. A total of $10,884 was realized by selling the stock at an average price of $11.78. This leaves the insider owning 76,765 shares of the company worth $0.73 million. Insiders disposed of 12,352 shares of company stock worth roughly $0.12 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NRIX stock. A new stake in Nurix Therapeutics Inc. shares was purchased by AFFINITY ASSET ADVISORS, LLC during the first quarter worth $762,000. TWO SIGMA INVESTMENTS, LP invested $350,000 in shares of NRIX during the first quarter. In the first quarter, PANAGORA ASSET MANAGEMENT INC acquired a new stake in Nurix Therapeutics Inc. valued at approximately $289,000. GSA CAPITAL PARTNERS LLP acquired a new stake in NRIX for approximately $266,000. AMERIPRISE FINANCIAL INC purchased a new stake in NRIX valued at around $216,000 in the second quarter. In total, there are 188 active investors with 94.40% ownership of the company’s stock.
A candlestick chart of Nurix Therapeutics Inc. (NASDAQ: NRIX) showed a price of $9.07 on Monday morning. During the past 12 months, Nurix Therapeutics Inc. has had a low of $7.52 and a high of $19.91. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.50, and a quick ratio of 4.50. The fifty day moving average price for NRIX is $10.67 and a two-hundred day moving average price translates $12.81 for the stock.
The latest earnings results from Nurix Therapeutics Inc. (NASDAQ: NRIX) was released for Aug, 2022. According to the Biotechnology Company, earnings per share came in at -$0.87, missing analysts’ expectations of -$0.79 by -0.08. This compares to -$0.85 EPS in the same period last year. The company reported revenue of $6.78 million for the quarter, compared to $7.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -8.29 percent. For the current quarter, analysts expect NRIX to generate $11.56M in revenue.
Nurix Therapeutics Inc.(NRIX) Company Profile
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
